MapLight Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
MPLT$7.44+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(120,860) | $(52,185) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 309 | 302 |
| Stock-based compensation expense | 18,262 | 360 |
| Net amortization of premiums and accretion of discounts on investments | (1,813) | (196) |
| Common stock issued to NeuroSolis, Inc. | — | 496 |
| Non-cash lease expense | 446 | 427 |
| Loss on disposal of property and equipment | 4 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 5,321 | (6,866) |
| Accounts payable | (1,237) | 190 |
| Accrued expenses | 3,961 | (838) |
| Operating lease liabilities | (441) | (374) |
| Deferred grant earnings | — | (833) |
| Net cash used in operating activities | (96,048) | (59,517) |
| Cash flows from investing activities | ||
| Purchases of short-term and long-term investments | (19,773) | — |
| Maturities and redemptions of investments | 147,530 | 55,000 |
| Purchases of property and equipment | (46) | (66) |
| Net cash provided by investing activities | 127,711 | 54,934 |
| Cash flows from financing activities | ||
| Payments of deferred offering costs | — | (211) |
| Proceeds from exercises of stock options | 93 | 8 |
| Proceeds from employee stock purchase plan issuances | 650 | — |
| Payment of employee tax obligations related to vesting of restricted stock units | (7,502) | — |
| Net cash used in financing activities | (6,759) | (203) |
| Increase (decrease) in cash, cash equivalents and restricted cash | 24,904 | (4,786) |
| Cash, cash equivalents and restricted cash at beginning of period | 46,936 | 38,460 |
| Cash, cash equivalents and restricted cash at end of period | $71,840 | $33,674 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Derecognition of right-of-use asset and lease liabilities | $3,374 | $— |
| Deferred financing costs included in accounts payable and accrued expenses | $— | $490 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.